| Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. | |
| | |
MedLine Citation:
|
PMID: 23208198 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Open-label extensions [studies SP516 (NCT00501969) and SP715 (NCT00594386)] of the CLEOPATRA-PD and PREFER studies were conducted to evaluate the safety, tolerability and efficacy of the dopaminergic agonist, rotigotine, over several years of follow-up in patients with advanced Parkinson's disease (PD). Eligible subjects completing the double-blind trials received open-label adjunctive rotigotine (≤16 mg/24 h) for up to 4 and 6 years in Studies SP516 and SP715, respectively. Safety and tolerability were assessed using adverse events, vital signs and laboratory parameters, and efficacy assessed using the unified Parkinson's disease rating scale (UPDRS). Of the 395 and 258 patients enrolled in the SP516 and SP715 studies, 48 and 45 % completed, respectively. Adverse events were typically dopaminergic effects [e.g., somnolence (18-25 %/patient-year), insomnia (5-7 %/patient-year), dyskinesias (4-8 %/patient-year) and hallucinations (4-8 %/patient-year)], or related to the transdermal application of a patch (application site reactions: 14-15 %/patient-year). There were no clinically relevant changes in vital signs or laboratory parameters in either study. Mean UPDRS part II (activities of daily living) and part III (motor function) total scores improved from double-blind baseline during dose titration, then gradually declined over the maintenance period. In study SP516, mean UPDRS part II and III total scores were 0.8 points above and 2.8 points below double-blind baseline, respectively, at end of treatment. In study SP715, mean UPDRS part II and III total scores were 4.1 points above and 0.2 points below baseline, respectively, at end of treatment. In these open-label studies, adjunctive rotigotine was efficacious with an acceptable safety and tolerability profile in patients with advanced PD for up to 6 years. |
| | |
Authors:
|
Peter A Lewitt; Babak Boroojerdi; Erwin Surmann; Werner Poewe |
Related Documents
:
|
23446068 - A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromy... 2493618 - Natural history vs. surgery for menière's disease. 22961538 - Early postoperative healing following buccal single flap approach to access intraosseou... 23336818 - Mycophenolate mofetil: a novel immunosuppressant in the treatment of dystrophic epiderm... 21791328 - Twenty-five year experience with balloon aortic valvuloplasty for congenital aortic ste... 22343478 - Airway complications after lung transplantation: long-term outcome of silicone stenting. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-12-4 |
Journal Detail:
|
Title: Journal of neural transmission (Vienna, Austria : 1996) Volume: - ISSN: 1435-1463 ISO Abbreviation: J Neural Transm Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9702341 Medline TA: J Neural Transm Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Neurology, Henry Ford Hospital, Detroit, MI, USA, plewitt1@hfhs.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The epidemiology of pain in Parkinson's disease.
Next Document: Children and Youth With Disabilities: Innovative Methods for Single Qualitative Interviews.